Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer
Abstract
Adoptive T cell based immunotherapy is gaining significant traction in cancer treatment. Despite its limited efficacy so far in treating solid tumors compared to hematologic cancers, recent advances in T cell engineering render this treatment increasingly more successful in solid tumors, demonstrating its broader therapeutic potential. In this paper we develop a mathematical model to study the efficacy of engineered T cell receptor (TCR) T cell therapy targeting the E7 antigen in cervical cancer cell lines. We consider a dynamical system that follows the population of cancer cells, TCR T cells, and IL-2 treatment concentration. We demonstrate that there exists a TCR T cell dosage window for a successful cancer elimination that can be expressed in terms of the initial tumor size. We obtain the TCR T cell dose for two cervical cancer cell lines: 4050 and CaSki. Finally, a combination therapy of TCR T cell and IL-2 treatment is studied. We show that certain treatment protocols can improve therapy responses in the 4050 cell line, but not in the CaSki cell line.
- Publication:
-
Journal of Theoretical Biology
- Pub Date:
- November 2020
- DOI:
- 10.1016/j.jtbi.2020.110403
- arXiv:
- arXiv:2001.10573
- Bibcode:
- 2020JThBi.50510403C
- Keywords:
-
- Adoptive T cell transfer;
- TCR T cells;
- IL-2 treatment;
- Combination cancer therapy;
- Mathematical oncology;
- Quantitative Biology - Populations and Evolution;
- Quantitative Biology - Tissues and Organs;
- 92B05
- E-Print:
- 8 pages, 7 figures